Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Assessment of drug half-life
Timeframe: Through study completion, an average of 4 weeks
Assessment of immune globulin G serum concentration after intravenous immune globulin G administration
Timeframe: Just before drug administration, immediately after drug administration, approximately days 7 and 14 post drug administration
Assessment of immune globulin G serum concentration after subcutaneous immune globulin G administration
Timeframe: Just before drug administration, immediately after drug administration, approximately days 2, 4 and 7 post drug administration